Metabolic dysfunction-associated steatotic liver disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes
At 6 or 12 months, depending on the progress made, the doctor might recommend keeping the same dose if there is no slowing of the weight loss, or if there is no further improvement for some time, so you may be switched to a higher dose
This change might also improve insurance coverage, as these medications are expressly validated for weight management
This is a serious concern because these drugs need careful patient selection, dose adjustment, and monitoring, he noted adding that unsupervised use can lead to complications like pancreatitis, kidney problems, or severe dehydration
When evaluating patients with CNS oedema of unclear origin or vasogenic cerebral oedema without identifable infectious or causative agent, it is imperative to include DEFICIT-syndrome in the differential diagnosis alongside HAE, and to conduct complete complement analysis and genetic investigations to achieve the correct diagnosis
If you only track one thing, track protein
